NewAmsterdam Pharma (Nasdaq:NAMS) granted equity awards under Nasdaq Listing Rule 5635(c)(4) to four non-executive new hires pursuant to its 2024 Inducement Plan.
The awards include share options on 28,700 ordinary shares at a $35.17 exercise price and 8,100 restricted stock units with multi-year vesting schedules.
The company detailed inducement grants of 28,700 options at $35.17 and 8,100 RSUs to four non-execut...
Analysis
The company detailed inducement grants of 28,700 options at $35.17 and 8,100 RSUs to four non-executive hires, vesting over three to four years. These routine compensation awards modestly expand share-based overhang; investors may watch for further equity grants or insider activity.
Key Figures
Inducement options granted:28,700 sharesOption exercise price:$35.17 per shareOption vesting term:4 years+3 more
6 metrics
Inducement options granted28,700 sharesAggregate options for four non-executive new hires
Option exercise price$35.17 per shareClosing market price on Nasdaq on July 1, 2026
Option vesting term4 years25% after one year, remaining monthly over 36 months
Inducement RSUs granted8,100 sharesAggregate RSUs for four non-executive new hires
RSU vesting term3 yearsOne-third on each of years one, two and three
Grant dateJuly 1, 2026Grant date for options and RSUs under inducement plan
Q1 2026 results, cash position and updates on Phase 3 programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent company news and events have generally coincided with modestly positive share-price reactions, with one notably strong move on the latest quarterly update.
Regulatory & Risk Context
Short Interest: 9.28%
Short Interest
9.28% of float
0%15%30%+
lowas of 2026-06-15Days to cover: 7.3
Reported short interest indicates relatively low short positioning, suggesting limited squeeze dynamics but also a moderate cushion against extreme volatility driven solely by covering activity.
"pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"The Compensation Committee ... approved the grant of restricted stock units covering an aggregate of 8,100 of NewAmsterdam’s ordinary shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise pricefinancial
"The share options have an exercise price per share equal to $35.17"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement planfinancial
"pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”)"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 28,700 of NewAmsterdam’s ordinary shares to four non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to $35.17, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on July 1, 2026, the grant date.The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 8,100 of NewAmsterdam’s ordinary shares to four non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units were granted on July 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.
About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
What inducement equity grants did NewAmsterdam Pharma (NAMS) announce on July 2, 2026?
NewAmsterdam Pharma announced inducement grants of share options on 28,700 ordinary shares and 8,100 restricted stock units to four non-executive new hires. According to NewAmsterdam, these awards were granted under its 2024 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).
What are the terms of the NewAmsterdam Pharma (NAMS) stock options granted on July 1, 2026?
The stock options cover 28,700 ordinary shares with a $35.17 exercise price, equal to the July 1, 2026 Nasdaq closing price. According to NewAmsterdam, options vest over four years, with 25% after one year and the rest in 36 monthly installments.
How do the NewAmsterdam Pharma (NAMS) restricted stock units for new hires vest?
NewAmsterdam granted 8,100 restricted stock units to four non-executive new hires, vesting over three years. According to NewAmsterdam, one-third of the units vest on each of the first, second, and third anniversaries of the vesting commencement date, subject to continued service.
Why did NewAmsterdam Pharma (NAMS) use Nasdaq Listing Rule 5635(c)(4) for these grants?
The company used Nasdaq Listing Rule 5635(c)(4) to issue inducement equity awards material to employment acceptance without prior shareholder approval. According to NewAmsterdam, the options and restricted stock units were granted under the 2024 Inducement Plan as part of this inducement framework.
Who is eligible for the July 2026 NewAmsterdam Pharma (NAMS) inducement grants?
The July 2026 inducement grants were made to four non-executive new hires at NewAmsterdam. According to NewAmsterdam, vesting of both stock options and restricted stock units depends on each employee’s continued service with the company on the applicable vesting dates.
